Treating sex steroid dependent cancer with bmx inhibitors

Abstract

The present invention provides methods, kits, and compositions for treating sex steroid dependent cancer using BMX inhibitors. In certain embodiments, a sample from a subject having, or suspected of having, a sex steroid dependent disease cancer, is further assayed to determine: i) if the subject is heterozygous or homozygous for the HSD3B1(1245C) allele that encodes for the 3βSD1(367T) protein. In some embodiments, the BMX inhibitor comprises a monoclonal antibody or BMX binding portion thereof (e.g., zanubrutinib, acalabrutinib, abivertinib or ibrutinib).

Dependencies are inferred from the claim text.